TRT Aveed denied as experimental or investigational by Humana?

Humana's specific coverage criteria for trt aveed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Aveed as Experimental

An "experimental or investigational" denial from Humana means they have determined — under their internal coverage criteria — that the evidence does not yet meet their threshold for established clinical benefit for your specific use case. For Aveed (testosterone undecanoate long-acting injection), this denial is surprising given its FDA-approved status for hypogonadism, but it can occur when the specific clinical context (e.g., a secondary diagnosis, an off-label indication, or a niche patient population) falls outside the way Humana has defined "established" coverage.

## Why This Denial Is Appealable

FDA approval is the federal government's determination that a drug is safe and effective for its labeled indication. An insurer's experimental classification that conflicts with an on-label FDA-approved use is legally vulnerable. If your use is on-label, this is one of the strongest grounds for appeal. State law and ERISA regulations both provide recourse. Under the ACA, plans cannot apply discriminatory benefit designs that effectively exclude FDA-approved treatments for covered conditions.

## Federal Appeal Framework

• Internal appeal: Submit within 180 days of the denial. Humana must respond within 30 days (72 hours expedited).
• External review (ACA §2719): Experimental/investigational denials are explicitly eligible for external review. After the internal denial, you have approximately 4 months to request an independent external review. An independent review organization will assess whether the denial meets the plan's own experimental criteria lawfully.
• Expedited review: Available when delay poses health risk — request it in writing simultaneously with the internal appeal if appropriate.

## Documentation to Gather

1. FDA-approved prescribing label — Download the current label from DailyMed (search "Aveed"). Highlight the approved indication and the specific population it covers. 2. Diagnosis confirmation — Chart documentation establishing hypogonadism diagnosis, symptom history, and relevant laboratory results. 3. Prescriber medical-necessity letter — Must state explicitly that the prescribed use is on-label, reference the FDA approval, cite the applicable professional society guideline (e.g., Endocrine Society guideline on male hypogonadism), and explain why this patient meets the labeled indication. 4. Humana's experimental/investigational policy — Request a copy in writing; verify the version date matches your denial date. The appeal should rebut each criterion Humana applied. 5. REMS documentation — Aveed is subject to a FDA REMS program requiring administration in a certified healthcare setting. Documentation that your provider is REMS-certified supports the on-label, clinically supervised nature of the use.

## Criteria-Mapping Structure

| Humana Experimental Criterion | Rebuttal Evidence | |---|---| | "Not FDA approved for this use" | FDA label excerpt showing approved indication | | "Insufficient evidence" | Prescriber letter + guideline organization reference | | "Not standard of care" | Relevant professional society guideline citation (organization name only, no statistics) |

Request the exact language of Humana's experimental/investigational policy that was applied to your claim. You are entitled to this under ERISA §503 and ACA rules. Build your appeal around each specific criterion they cited.